Creative Visionary Nicola Formichetti Named Global Creative Director, M·A·C Cosmetics
NEW YORK, May 14, 2025--(BUSINESS WIRE)--The Estée Lauder Companies (NYSE:EL) and M·A·C Cosmetics announced today the appointment of Nicola Formichetti as Global Creative Director, effective May 19, 2025. A celebrated creative director, designer, and cultural icon, Formichetti brings his visionary artistry, genre-defying creativity and consumer-first mindset to the helm of M·A·C's global creative strategy. He will report directly to Aïda Moudachirou-Rébois, M·A·C's Senior Vice President and Global General Manager.
Formichetti's appointment marks a pivotal moment for M·A·C as the brand continues to shape the future of beauty through boundary-pushing innovation and cultural relevance. His dynamic approach to creativity, rooted at the intersection of fashion, music, culture, and technology, will spark new levels of desirability for M·A·C, driving its product innovation, creative collaborations, and global consumer engagement. In his new role, Formichetti will shape the strategy, conceptualization and execution of M·A·C's creative vision, elevating the brand's global image and impact across every touchpoint – from campaigns and social media platforms to product, packaging, and immersive retail experiences. At its core, M·A·C is built on artistry – and as an artist and visionary himself, Formichetti will play a central role in reimagining what artistry means for the next generation of consumers. He will lead a multidisciplinary creative team, building on the brand's iconic heritage in artistry, trendsetting, limitless self-expression and individuality to deliver bold storytelling that leaves a lasting impression on a global scale.
"Nicola is a once-in-a-generation creative talent who perfectly embodies the bold, fearless energy of M·A·C and our global community," said Aïda Moudachirou-Rébois. "Like our consumers, Nicola is passionate, expressive and knows how to push boundaries. His appointment is not only a celebration of artistry, but a reflection of our commitment to serving our consumers with of-the-moment relevance, creativity and authenticity. He is the perfect Creative Director to drive the brand into its next exciting chapter."
Renowned for his genre-defying work with global superstars like Lady Gaga, his creative oversight of some of fashion's most influential houses, and his reputation for trend-defining collaborations, Formichetti is uniquely equipped to help M·A·C deliver on its mission to be a brand for "All Ages, All Races, All Genders." Drawing from his Japanese and Italian heritage, he brings a globally attuned perspective that resonates deeply with M·A·C's inclusive ethos. His forward-thinking approach seamlessly integrates technology and digital innovation, pushing creative boundaries and redefining how beauty and fashion engage with global audiences.
"Nicola's appointment is a bold step forward for M·A·C and for The Estée Lauder Companies," said Jane Hertzmark Hudis, Executive Vice President, Chief Brand Officer, The Estée Lauder Companies. "Nicola brings the vision, bold creativity and track record to take the M·A·C brand to new heights as it enters its next phase of growth. We are thrilled to bring this level of high-caliber creative talent to The Estée Lauder Companies."
"This appointment represents yet another definitive step forward for The Estée Lauder Companies as we execute our recently announced Beauty Reimagined vision, which is focused on becoming the most consumer-centric prestige beauty company in the world," said Stéphane de La Faverie, President and CEO, The Estée Lauder Companies. "A key component of Beauty Reimagined is meeting consumers where they are, and with Nicola's unique ability to capture the pulse of culture, he will help shape exciting and innovative products and experiences. M·A·C's tremendous brand equity is most powerful when it evolves with the times—and Nicola will leverage his creative vision to inspire a new generation of connection, self-expression, and loyalty."
"M·A·C is an iconic brand that has always championed the people and communities that move culture forward," said Formichetti. "Having previously collaborated with the brand on my Nicopanda collection and the M·A·C VIVA GLAM campaign, I'm thrilled to return and bring my vision to this next chapter. The world is craving creativity, beauty, and connection—and I can't wait to help bring that to life in a magical way."
Cautionary Note Regarding Forward-Looking StatementsStatements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company's expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement its strategy, including the Company's profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder CompaniesThe Estée Lauder Companies Inc. is one of the world's leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company's products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
ELC-LELC-B
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514389264/en/
Contacts
Media Relations: Diederik Koenders dkoenders@maccosmetics.com
Investor Relations: Rainey Mancini rmancini@estee.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
Essential Properties Realty Trust, Inc. Announces Pricing of $400 Million of 5.400% Senior Notes due 2035
PRINCETON, N.J.--(BUSINESS WIRE)--Essential Properties Realty Trust, Inc. (NYSE: EPRT; the 'Company') announced today that its operating partnership, Essential Properties, L.P. (the 'Operating Partnership'), has priced a public offering of $400 million aggregate principal amount of 5.400% Senior Notes due 2035 (the 'Notes'). The Notes were priced at 98.317% of the principal amount and will mature on December 1, 2035. The offering is expected to settle on August 21, 2025, subject to the satisfaction of customary closing conditions. The Notes will be fully and unconditionally guaranteed by the Company. The Operating Partnership intends to use the net proceeds from the offering (i) to repay amounts outstanding under its revolving credit facility and (ii) for general corporate purposes, including funding future investment activity. Wells Fargo Securities, Mizuho, BMO Capital Markets, BofA Securities, Capital One Securities, TD Securities and Truist Securities are acting as joint book-running managers for the offering. Barclays, BNP PARIBAS, Citigroup, Citizens Capital Markets, Goldman Sachs & Co. LLC, Huntington Capital Markets, Morgan Stanley, Regions Securities LLC, Scotiabank, Stifel and Wolfe Capital Markets and Advisory are acting as co-managers for the offering. The offering is being made pursuant to an effective shelf registration statement filed by the Company and the Operating Partnership with the Securities and Exchange Commission (the 'SEC'). A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, a copy of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attention: WFS Customer Service, toll-free at 1-800-645-3751; or Mizuho Securities USA LLC, Attention: Debt Capital Markets, 1271 Avenue of the Americas, New York, NY 10020, at 1-866-271-7403, or by visiting the EDGAR database on the SEC's web site at This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. When used in this press release, the words 'expect' and 'will,' or the negative of these words, or similar words or phrases that are predictions of or indicate future events and that do not relate solely to historical matters, are intended to identify forward-looking statements. You can also identify forward-looking statements by discussions regarding strategy, plans or intentions. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise. The Company does not guarantee that the transactions and events described will happen as described (or that they will happen at all). You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. While forward-looking statements reflect the Company's good faith beliefs, they are not guarantees of future performance. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. In light of these risks and uncertainties, the forward-looking events discussed in this press release might not occur as described, or at all. Additional information concerning factors that could cause actual results to differ materially from these forward-looking statements is contained from time to time in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. Copies of each filing may be obtained from the Company or the SEC. Such forward-looking statements should be regarded solely as reflections of the Company's current plans and estimates. Actual results may differ materially from what is expressed or forecast in this press release. About Essential Properties Realty Trust, Inc. Essential Properties Realty Trust, Inc. is an internally managed real estate investment trust that acquires, owns and manages primarily single-tenant properties that are net leased on a long-term basis to companies operating service-oriented or experience-based businesses. As of June 30, 2025, the Company's portfolio consisted of 2,190 freestanding net lease properties with a weighted average lease term of 14.3 years and a weighted average rent coverage ratio of 3.4x. In addition, as of June 30, 2025, the Company's portfolio was 99.6% leased to tenants operating 606 different concepts across 48 states.
Business Wire
12 minutes ago
- Business Wire
Cybin Announces Results of Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the ' Meeting '). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: 1. Appointment of Auditor Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below: 2. Number of Directors The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below: 3. Election of Directors Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below: George Tziras did not stand for re-election as a director. The Company thanks Mr. Tziras for his past service. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Business Wire
12 minutes ago
- Business Wire
Capvidia brings MBD for Suppliers with browser-based 3D human-viewable models linked to QIF/STEP
CHICAGO--(BUSINESS WIRE)-- Capvidia, a global leader in Model-Based Definition (MBD) and Model-Based Enterprise (MBE) software, announced a major milestone for MBDVidia: 3D human-viewable HTML models synchronized with QIF and STEP AP242. The result is OEM MBD that suppliers can use anywhere with no CAD required. How it works: MBDVidia publishes standards-based QIF/STEP from native CAD (Creo, CATIA, SOLIDWORKS, Autodesk, etc.) and now generates a linked HTML viewable (and PDF). Any browser can open the interactive 3D model and PMI, giving procurement, manufacturing, quality, and the shop floor a shared, authoritative view in a user-friendly way. Why it matters for Suppliers: No CAD seats: Open interactive 3D + PMI in any modern browser. Faster RFQs: See features, GD&T, and tolerances in 3D to quote accurately. Fewer errors: Viewable is linked to QIF/STEP and native CAD—preserves intent. Bill of Characteristics click-through: Jump from each characteristic to the exact PMI on the model. Shop-floor friendly: Zoom, section, filter PMI; run on tablets or kiosks. Quality ready: Linked QIF speeds FAI/PPAP and audit-ready traceability. Clear changes: Model-to-characteristic traceability improves ECO handling. Start 2D → scale 3D: Use HTML as a low-friction on-ramp from PDFs. 'Capvidia is about simplifying collaboration between OEMs and suppliers,' said Tomasz Luniewski, CEO of Capvidia. 'By pairing standards-based QIF/STEP with an interactive browser view, we make MBD universally accessible so quoting, programming, and quality teams can move faster with fewer mistakes.' Learn more: MBDVidia at Get MBD ready: Request a demo at About Capvidia Capvidia is the global authority on MBD/MBE. We make the 3D model the single source of truth, auto-generating PMI and characteristics to eliminate manual ballooning and automate workflows from design through quality. Built on open standards (QIF, STEP AP242) and native CAD, our software delivers true interoperability across CAD, CAM, CMM, and PLM—without loss of intent. The result is a complete, auditable, traceable digital thread linking every requirement to real-world results across OEMs and suppliers. Trusted by leading aerospace, defense, medical-device, and industrial manufacturers, Capvidia helps teams move faster, prove conformance, and collaborate with confidence.
